Pulmonary Embolism

Pulmonary Embolism – High‑Yield Study Guide for Medical Students

Definition

Pulmonary embolism (PE) is an acute obstruction of one or more branches of the pulmonary artery, most commonly by thrombus originating from the deep veins of the lower extremities or pelvis (part of the venous thromboembolism spectrum with deep vein thrombosis, DVT). PE impairs pulmonary blood flow, causing ventilation–perfusion (V/Q) mismatch, increased pulmonary vascular resistance, and potentially right ventricular (RV) failure and sudden death.^[5],[6]

Epidemiology

PE is a common and potentially fatal condition, with an annual incidence in developed countries estimated at roughly 60–100 per 100,000 population, varying by age and risk factors. It represents a major cause of cardiovascular morbidity and mortality, along with myocardial infarction and stroke.^[5]

Venous thromboembolism (VTE), which includes DVT and PE, is prevalent worldwide, and population-based studies show substantial lack of awareness of VTE risk factors and symptoms among the general public, highlighting the importance of prevention and early recognition.^[1],[9]

Pathophysiology

Most PEs arise from thrombi in the deep veins of the legs or pelvis that embolize to the pulmonary arterial tree. The underlying thrombus formation is driven by Virchow’s triad: venous stasis, endothelial injury, and hypercoagulability. Once in the pulmonary circulation, emboli cause abrupt vascular obstruction.

The key pathophysiologic consequences include:

• Increased pulmonary vascular resistance: Obstruction plus reflex vasoconstriction elevate pulmonary artery pressures, increasing RV afterload.
• Right ventricular strain and failure: The RV dilates and may fail acutely in significant PE, leading to decreased left ventricular (LV) preload, reduced cardiac output, hypotension, and shock.
• Ventilation–perfusion mismatch: Areas of ventilated lung are underperfused (dead space), causing hypoxemia; compensatory tachypnea and hyperventilation are common.
• Hemodynamic spectrum: High-risk (massive) PE presents with sustained hypotension, obstructive shock, or cardiac arrest, whereas intermediate-risk (submassive) PE has RV dysfunction without systemic hypotension, and low-risk PE lacks both.^[3],[8]

Clinical Presentation

PE has a broad clinical spectrum, from asymptomatic incidental findings to sudden cardiovascular collapse. A high index of suspicion is essential because clinical features are nonspecific.

Common symptoms:

• Dyspnea (sudden onset or subacute)
• Pleuritic chest pain
• Cough, sometimes with hemoptysis
• Syncope or presyncope (especially in large PE)
• Anxiety or sense of impending doom

Common signs:

• Tachypnea (most sensitive sign)
• Tachycardia
• Hypoxemia (may be mild or even normal early)
• Hypotension, signs of shock in high-risk PE
• Signs of DVT: unilateral leg swelling, pain, tenderness, erythema
• Jugular venous distension, RV heave in massive/submassive PE

Presentations can vary by risk phenotype. High-risk PE includes patients with cardiac arrest, obstructive shock, or sustained hypotension and is associated with high early mortality.^[3],[8]

Risk Factors

Risk factors largely overlap with those for VTE:

• Stasis: prolonged immobility, recent surgery (especially orthopedic), long-haul travel, paralysis
• Endothelial injury: trauma, surgery, central venous catheters
• Hypercoagulability: malignancy, pregnancy/postpartum, oral contraceptives or estrogen therapy, thrombophilias (e.g., Factor V Leiden, prothrombin mutation, antiphospholipid syndrome)
• Other: prior VTE, obesity, heart failure, chronic respiratory disease, older age

Population data show that many individuals with these risk factors are unaware of their association with VTE, contributing to delayed diagnosis.^[1],[9]

Diagnostic Approach

Diagnosis combines clinical probability assessment, D‑dimer testing, and imaging. Overuse of imaging is common, so validated clinical decision rules are essential.

Clinical Probability Assessment

Several clinical decision rules help stratify patients into low, intermediate, or high pretest probability categories, improving diagnostic yield:

• Wells score for PE: incorporates clinical signs of DVT, alternative diagnosis less likely than PE, heart rate >100, recent immobilization or surgery, prior VTE, hemoptysis, and malignancy.
• Revised Geneva score: uses age, heart rate, recent surgery or fracture, previous DVT/PE, hemoptysis, active cancer, unilateral lower limb pain, and pain on deep venous palpation with unilateral edema.
• Other tools: PERC (Pulmonary Embolism Rule-out Criteria) for very low-risk ED patients; YEARS algorithm, etc.

Cross-sectional analyses of multiple PE decision rules emphasize that no single rule is perfect; an integrated, context-specific approach (combining clinical judgment, rules, and local practice patterns) is recommended.^[6]

Laboratory Testing

• D-dimer: Highly sensitive but nonspecific. In patients with low or intermediate pretest probability, a negative high-sensitivity D-dimer can effectively exclude PE without imaging. Age-adjusted thresholds are often used in older adults.
• Arterial blood gas: May show hypoxemia and respiratory alkalosis, but can be normal. Not diagnostic.
• Cardiac biomarkers (troponin, BNP/NT-proBNP): Elevation suggests RV strain and is useful for risk stratification rather than diagnosis.^[7]

Imaging

• CT pulmonary angiography (CTPA): First-line imaging in most settings. Directly visualizes emboli in the pulmonary arteries, assesses clot burden, and can provide indirect signs of RV strain. Rapid and widely available.^[5]
• Ventilation–perfusion (V/Q) scan: Preferred when CTPA is contraindicated (e.g., severe contrast allergy, pregnancy in some centers, severe renal dysfunction). A normal perfusion scan essentially excludes clinically significant PE.
• Compression ultrasonography of lower extremities: Detects DVT; a positive proximal DVT in a patient with suspected PE may be sufficient to justify treatment when chest imaging is not feasible.
• Transthoracic echocardiography (TTE): Not diagnostic of PE per se, but can show RV dilation, dysfunction, elevated pulmonary pressures, and occasionally visible right heart thrombus. In hemodynamically unstable patients, echo helps determine likelihood of high-risk PE and the need for emergent reperfusion therapy.^[3],[8]

Risk Stratification

After confirming PE, risk stratification guides management:

• High-risk (massive) PE: PE associated with sustained hypotension, obstructive shock, or cardiac arrest. High early mortality; consider systemic thrombolysis or other reperfusion strategies.^[3],[8]
• Intermediate-risk (submassive) PE: Hemodynamically stable but with RV dysfunction (on echo or CTPA) and/or elevated cardiac biomarkers. These patients are at risk for decompensation and require close monitoring.
• Low-risk PE: Hemodynamically stable, no RV dysfunction or biomarker elevation, favorable clinical scores (e.g., low PESI/sPESI). May be candidates for early discharge or outpatient therapy.^[4],[7]

Recent work suggests that combining clinical variables, serum biomarkers, and imaging/radiomic features can improve prediction of short-term adverse outcomes in acute PE.^[4],[7]

Management

Management strategies center on hemodynamic stabilization, anticoagulation, and selective use of reperfusion therapies. Multidisciplinary Pulmonary Embolism Response Teams (PERT) are increasingly used to individualize care in complex cases.^[5],[3]

Initial Stabilization

• Airway and breathing: Oxygen supplementation to maintain adequate saturation; intubation if necessary (careful to avoid worsening RV afterload with high intrathoracic pressures).
• Circulation: IV access, cautious fluid resuscitation (small boluses) in hypotensive patients, vasopressors (e.g., norepinephrine) for shock.

Anticoagulation

Immediate anticoagulation is the cornerstone of PE treatment in hemodynamically stable patients and in high-risk patients once lysis or embolectomy decisions are made.

• Parenteral options:
  • Unfractionated heparin (UFH) IV infusion (preferred if high bleeding risk, renal failure, or anticipated procedures/thrombolysis).
  • Low-molecular-weight heparin (LMWH) SC (e.g., enoxaparin) – often preferred in stable patients, including many with cancer.
• Direct oral anticoagulants (DOACs):
  • Apixaban, rivaroxaban: can be used as initial and long-term therapy in many patients.
  • Edoxaban, dabigatran: typically started after a parenteral lead-in.
• Vitamin K antagonists (warfarin): Require bridging with parenteral heparin until INR therapeutic (2.0–3.0); now less commonly used as first-line when DOACs are available.

Duration of therapy is typically at least 3 months, with longer or indefinite therapy for unprovoked PE, recurrent VTE, or persistent risk factors, balanced against bleeding risk.

Reperfusion Strategies for High-Risk PE

In high-risk PE with hemodynamic instability, early reperfusion can be lifesaving.

• Systemic thrombolysis: IV alteplase (e.g., 100 mg over 2 hours) is standard; alternative dosing regimens exist. Benefits include rapid reduction in pulmonary artery pressures and RV afterload, but bleeding risk (including intracranial hemorrhage) is significant.^[3],[8]
• Catheter-directed therapies: Catheter-directed thrombolysis (low-dose local lytics) and mechanical thrombectomy are options when systemic thrombolysis is contraindicated or has failed, or to minimize bleeding risk in selected patients.
• Surgical embolectomy: Considered when thrombolysis is contraindicated or ineffective, especially in centers with cardiothoracic surgical expertise.

Intermediate-Risk (Submassive) PE Management

These patients are hemodynamically stable but have RV dysfunction and/or positive troponin. The mainstay is anticoagulation plus close monitoring in a setting where decompensation can be rapidly managed. Routine systemic thrombolysis is generally not recommended due to bleeding risk, but rescue reperfusion is considered if deterioration occurs. Catheter-directed options may be considered in selected patients.^[3],[8]

Low-Risk PE Management

Low-risk patients (stable hemodynamics, no RV dysfunction, low clinical risk scores) are treated with anticoagulation alone and may qualify for early discharge or outpatient management if good follow-up is available.

Inferior Vena Cava (IVC) Filters

IVC filters are reserved for patients with acute VTE who have an absolute contraindication to anticoagulation or who develop recurrent PE despite adequate anticoagulation. Filters should be retrieved as soon as the indication resolves.

Prognosis and Outcomes

Early mortality is highest in high-risk PE, especially those presenting with cardiac arrest, obstructive shock, or persistent hypotension.^[3],[8] Intermediate-risk patients have a substantial risk of clinical deterioration, while low-risk cases generally have favorable short-term outcomes when appropriately treated.^[4],[7]

Prevention

Because PE is largely preventable, prophylaxis in at-risk patients is crucial.

• Pharmacologic prophylaxis with low-dose LMWH, UFH, or DOACs in high-risk hospitalized or postoperative patients.
• Mechanical prophylaxis with intermittent pneumatic compression devices and early mobilization, especially when pharmacologic prophylaxis is contraindicated.
• Risk assessment models are used in hospital settings to determine which patients need prophylaxis.

Community studies highlight gaps in public knowledge about VTE, suggesting that improved education and awareness could reduce incidence and delays in care.^[1],[9]

Key Clinical Pearls for Medical Students

• Always estimate pretest probability using a validated clinical decision rule (e.g., Wells, Geneva) plus clinical judgment before ordering D-dimer or imaging.^[6]
• In low or intermediate pretest probability, a negative high-sensitivity D-dimer effectively excludes PE, reducing unnecessary CTPA.
• Tachypnea and tachycardia are common but nonspecific; unexplained dyspnea or pleuritic chest pain in a patient with risk factors should trigger consideration of PE.
• Risk stratification after diagnosis (high, intermediate, low risk) is as important as making the diagnosis, because it directly informs management decisions, especially regarding thrombolysis or catheter-based interventions.^[3],[4]
• High-risk (massive) PE is a true cardiovascular emergency that requires rapid recognition and consideration of systemic thrombolysis or other reperfusion strategies.^[3],[8]
• Persistent dyspnea after PE should prompt evaluation for chronic thromboembolic pulmonary hypertension (CTEPH), a potentially curable cause of pulmonary hypertension.
• VTE and PE are under-recognized by the public; incorporating prevention and patient education into clinical practice can significantly impact outcomes.^[1],[9]
• Educational tools and simulation, including case-based learning and gamified approaches, can help solidify learners’ understanding of PE recognition, workup, and disposition decisions.^[5],[2],[10]

Summary

Pulmonary embolism is a common, potentially fatal condition that sits at the intersection of cardiology, pulmonology, emergency medicine, and hematology. For medical students, mastery of PE involves recognizing risk factors and variable presentations, applying structured diagnostic algorithms, understanding the hemodynamic implications of RV strain, and knowing when to escalate to advanced therapies. Integrating evidence-based decision rules with thoughtful clinical judgment is essential for safe and effective care in patients with suspected or confirmed PE.^[5],[6],[3]